Dr. Brian Nahed specializes in Brain Tumors (Glioblastoma, Gliomas, Meningiomas, and Metastatic Brain Tumors) and Spinal Disorders. He is an Assistant Professor and Neurosurgeon in the Department of Neurosurgery and Pappas Center for Neurooncology.
BiographyDr. Brian Nahed specializes on brain tumors (glioblastoma, gliomas, metastatic brain tumors, and meningiomas) as well as Spinal Disorders.
He was born in New York. He attended University of California at Los Angeles where he majored in Neuroscience, graduating Phi Beta Kappa. He attended the Yale School of Medicine where he was awarded the Doris Duke Clinical Research Fellowship to study the genetics of intrancranial aneurysms. He completed internship and neurosurgery residency at the Massachusetts General Hospital. He was a postdoctoral fellow in the laboratory of Drs. Daniel Haber and Shyamala Maheswaran.
Dr. Nahed joined the MGH Department of Neurosurgery and the Brain Tumor Center in 2011. He is an assistant professor and teaching faculty member of Harvard Medical School. Dr. Brian Nahed's research focuses on circulating brain tumor cells and metastatic disease. In collaboration with Drs. Daniel Haber and Shyamala Maheswaran, Dr. Nahed's research has received several grants and awards and has been presented at national conferences. Dr. Nahed is actively enrolling patients with brain tumors into his research study.
Dr. Brian Nahed is an active member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, and serves on national committees for the Tumor Section and Council of State Neurological Surgeons. He is serves as a neurotrauma consultant for the National Football League (NFL).
Circulating Brain Tumor Cells
Metastatic Disease of the Brain and Spine
Dr. Brian Nahed's research focuses on identifying and analyzing circulating tumor cells in the blood of patients with brain cancer. Through a collaboration between bioengineers, molecular biologists and clinicians, a circulating tumor cell capture device was developed to capture and detect tumor cells from patients with cancer. Under the mentorship of Drs. Daniel Haber, Shyamala Maheswaran, and Mehmet Toner, they aim to harness this technology to genetically characterize tumor cells without needing an invasive biopsy, and determine responsiveness to targeted cancer drugs. It also offers the opportunity to study cancer stem cells or @ metastasis precursors, thought to be at the origin of cancer spread via the bloodstream, to define their molecular vulnerabilities and help design new therapies to prevent cancer metastasis.
84 peer-reviewed publications to date. Please refer to pub med link for articles.